Corbus Pharmaceuticals Holdings, Inc. (CRBP) Income Statement Analysis

See more : Reinsurance Group of America, Incorporated (RZB) Income Statement Analysis – Financial Results

Complete financial analysis of Corbus Pharmaceuticals Holdings, Inc. (CRBP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Corbus Pharmaceuticals Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

EssilorLuxottica Société anonyme (EL.PA) Income Statement Analysis – Financial Results
Connexion Telematics Ltd (CXZ.AX) Income Statement Analysis – Financial Results
Minth Group Limited (MNTHY) Income Statement Analysis – Financial Results
KUKA Aktiengesellschaft (0JOE.L) Income Statement Analysis – Financial Results
Eletrobras Participações S.A. – Eletropar (LIPR3.SA) Income Statement Analysis – Financial Results

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.corbuspharma.com

About Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	0.00	0.00	881.71K	3.94M	36.14M	4.82M	2.44M	1.91M	648.38K	0.00	0.00	0.00
Cost of Revenue	31.17M	1.49M	1.64M	98.27K	89.60K	48.61M	26.04M	15.44M	5.89M	1.26M	0.00	0.00
Gross Profit	-31.17M	-1.49M	-757.53K	3.84M	36.05M	-43.79M	-23.60M	-13.53M	-5.24M	-1.26M	0.00	0.00
Gross Profit Ratio	0.00%	0.00%	-85.92%	97.50%	99.75%	-908.11%	-967.09%	-707.60%	-808.21%	0.00%	0.00%	0.00%
Research & Development	31.17M	16.14M	36.45M	98.27M	89.60M	48.61M	26.04M	15.44M	5.89M	1.26M	210.67K	575.09
General & Administrative	13.91M	18.70M	20.43M	28.48M	23.64M	12.96M	8.96M	6.46M	3.61M	1.39M	346.61K	289.05
Selling & Marketing	-641.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	13.27M	18.70M	20.43M	28.48M	23.64M	12.96M	8.96M	6.46M	3.61M	1.39M	346.61K	289.05
Other Expenses	-30.53M	-48.77K	11.90M	13.27M	4.58M	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	13.91M	34.84M	56.87M	126.75M	113.25M	61.57M	35.00M	21.90M	9.50M	2.65M	557.28K	827.22
Cost & Expenses	45.08M	34.84M	56.87M	126.75M	113.25M	61.57M	35.00M	21.90M	9.50M	2.65M	557.28K	827.22
Interest Income	0.00	0.00	1.83K	1.03K	1.23M	982.78K	183.11K	477.00	3.42K	2.12K	754.00	59.74
Interest Expense	2.92M	2.13M	1.83M	1.03M	19.03K	0.00	183.11K	0.00	2.44K	24.02K	45.11K	0.00
Depreciation & Amortization	641.00K	1.49M	1.64M	1.69M	1.23M	493.94K	255.65K	87.66K	43.94K	10.41K	754.00	824.15
EBITDA	-44.44M	-38.73M	-54.97M	-121.69M	-76.37M	-56.25M	-32.31M	-19.90M	-8.81M	-2.64M	-556.52K	-62.81
EBITDA Ratio	0.00%	0.00%	-6,381.74%	-3,101.40%	-212.89%	-1,178.71%	-1,332.72%	-1,040.23%	-1,358.20%	0.00%	0.00%	0.00%
Operating Income	-45.08M	-39.84M	-55.99M	-122.81M	-77.10M	-56.75M	-32.56M	-19.99M	-8.85M	-2.65M	-557.28K	-824.15
Operating Income Ratio	0.00%	0.00%	-6,350.09%	-3,119.20%	-213.33%	-1,176.78%	-1,334.43%	-1,045.56%	-1,365.51%	0.00%	0.00%	0.00%
Total Other Income/Expenses	473.99K	-2.51M	10.35M	11.54M	5.65M	1.08M	141.20K	-13.62K	2.95K	106.69K	-45.07K	-62.81
Income Before Tax	-44.60M	-42.35M	-45.64M	-111.27M	-71.45M	-55.67M	-32.42M	-20.00M	-8.85M	-2.54M	-602.35K	-886.96
Income Before Tax Ratio	0.00%	0.00%	-5,176.38%	-2,826.08%	-197.69%	-1,154.48%	-1,328.65%	-1,046.27%	-1,365.05%	0.00%	0.00%	0.00%
Income Tax Expense	0.00	13.49M	-87.84K	35.05K	-2.30M	1.08M	-396.86K	13.62K	2.44K	24.02K	44.36K	-62.81
Net Income	-44.60M	-55.83M	-45.55M	-111.30M	-69.15M	-55.67M	-32.42M	-20.00M	-8.85M	-2.54M	-602.35K	-886.96
Net Income Ratio	0.00%	0.00%	-5,166.42%	-2,826.97%	-191.33%	-1,154.48%	-1,328.65%	-1,046.27%	-1,365.05%	0.00%	0.00%	0.00%
EPS	-10.31	-13.39	-11.11	-42.74	-32.47	-29.30	-19.38	-14.58	-8.47	-3.78	-0.70	-3.82
EPS Diluted	-10.31	-13.39	-11.11	-42.74	-32.47	-29.30	-19.38	-14.58	-8.47	-3.78	-0.70	-3.82
Weighted Avg Shares Out	4.33M	4.17M	4.10M	2.60M	2.13M	1.90M	1.67M	1.37M	1.05M	672.00K	860.06K	232.00
Weighted Avg Shares Out (Dil)	4.33M	4.17M	4.10M	2.60M	2.13M	1.90M	1.67M	1.37M	1.05M	672.00K	860.06K	232.16

Corbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701

October 16, 2023globenewswire.com

NORWOOD, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced that a poster characterizing the pre-clinical validation of CRB-701, a next generation antibody drug conjugate (ADC)...

Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert' Series (Session 2) on CRB-701 on October 10, 2023

October 3, 2023globenewswire.com

NORWOOD, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that it will host a Virtual ‘Meet the Expert' event on the development of a next...

Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on its Anti-aVb8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting

September 27, 2023prnewswire.com

NORWOOD, Mass. , Sept. 27, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that an abstract highlighting pre-clinical data on its CRB-601 anti-aVb8 integrin monoclonal antibody has been accepted...

Corbus Pharmaceuticals to Present Pre-Clinical Data Characterizing its CRB-701 Nectin-4 ADC at the at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

September 19, 2023prnewswire.com

NORWOOD, Mass. , Sept. 19, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced the pre-clinical data on its CRB-701 Nectin-4 anti-drug-conjugate (ADC) will be presented at the 2023 AACR-NCI-EORTC International...